The differential roles of Slit2-exon 15 splicing variants in angiogenesis and HUVEC permeability
- 29 May 2015
- journal article
- Published by Springer Nature in Angiogenesis
- Vol. 18 (3) , 301-312
Abstract
Slit2, a secreted glycoprotein, is down-regulated in many cancers. Slit2/Robo signaling pathway plays an important, but controversial, role in angiogenesis. We identified splicing variants of Slit2 at exon 15, Slit2-WT and Slit2-ΔE15, with differential effects on proliferation and invasive capability of lung cancer cells. The aim of this study was to elucidate the differential roles of these exon 15 splicing variants in angiogenesis. Our results revealed that both Slit2-WT and Slit2-ΔE15 inhibit motility of human umbilical vein endothelial cells (HUVECs). The conditioned medium (CM) collected from CL1-5/VC or CL1-5/Slit2-WT lung adenocarcinoma cells blocked HUVEC tube formation and angiogenesis on chorioallantoic membrane (CAM) assay when compared with untreated HUVECs and CAM, respectively. However, CM of CL1-5/Slit2-ΔE15 restored the quality of tubes and the size of vessels. Although both Slit2-WT and Slit2-ΔE15 inhibited permeability induced by CM of cancer cells, Slit2-ΔE15 exhibited stronger effect. These results suggested that Slit2-ΔE15 plays important roles in normalization of blood vessels by enhancing tube quality and tightening endothelial cells, while Slit2-WT only enhances tightening of endothelial cells. It appears that Robo4 is responsible for Slit2 isoform-mediated inhibition of permeability, while neither Robo1 nor Robo4 is required for Slit2-ΔE15-enhanced tube quality. The results of this study suggest that Slit2-ΔE15 splicing form is a promising molecule for normalizing blood vessels around a tumor, which, in turn, may increase efficacy of chemotherapy and radiotherapy.Keywords
Funding Information
- National Science Council Grant (NSC 102-2320-B-040 -010 -MY2(Taiwan, R.O.C.))
- Inter-institutional grant (CSMU-TTM-099004(Taiwan, R.O.C.))
- National Science Council Grant (NSC 102-2320-B040-006-MY3(Taiwan, R.O.C.))
This publication has 36 references indexed in Scilit:
- Antiangiogenic therapy—evolving view based on clinical trial resultsNature Reviews Clinical Oncology, 2012
- Molecular mechanisms and clinical applications of angiogenesisNature, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Slit2 inhibits glioma cell invasion in the brain by suppression of Cdc42 activityNeuro-Oncology, 2009
- Slit2 Inhibits Growth and Metastasis of Fibrosarcoma and Squamous Cell CarcinomaNeoplasia, 2008
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Slit2 involvement in glioma cell migration is mediated by Robo1 receptorJournal of Neuro-Oncology, 2007
- Inhibition of medulloblastoma cell invasion by SlitOncogene, 2006
- Robo4 Signaling in Endothelial Cells Implies Attraction Guidance MechanismsJournal of Biological Chemistry, 2006
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005